Literature DB >> 12896876

Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha.

Timothy D Le Cras1, William D Hardie, Karen Fagan, Jeffrey A Whitsett, Thomas R Korfhagen.   

Abstract

Pulmonary vascular disease plays a major role in morbidity and mortality in infant and adult lung diseases in which increased levels of transforming growth factor (TGF)-alpha and its receptor EGFR have been associated. The aim of this study was to determine whether overexpression of TGF-alpha disrupts pulmonary vascular development and causes pulmonary hypertension. Lung-specific expression of TGF-alpha in transgenic mice was driven with the human surfactant protein (SP)-C promoter. Pulmonary arteriograms and arterial counts show that pulmonary vascular development was severely disrupted in TGF-alpha mice. TGF-alpha mice developed severe pulmonary hypertension and vascular remodeling characterized by abnormally extensive muscularization of small pulmonary arteries. Pulmonary vascular development was significantly improved and pulmonary hypertension and vascular remodeling were prevented in bi-transgenic mice expressing both TGF-alpha and a dominant-negative mutant EGF receptor under the control of the SP-C promoter. Vascular endothelial growth factor (VEGF-A), an important angiogenic factor produced by the distal epithelium, was decreased in the lungs of TGF-alpha adults and in the lungs of infant TGF-alpha mice before detectable abnormalities in pulmonary vascular development. Hence, overexpression of TGF-alpha caused severe pulmonary vascular disease, which was mediated through EGFR signaling in distal epithelial cells. Reductions in VEGF may contribute to the pathogenesis of pulmonary vascular disease in TGF-alpha mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12896876     DOI: 10.1152/ajplung.00045.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  22 in total

Review 1.  Lung organogenesis.

Authors:  David Warburton; Ahmed El-Hashash; Gianni Carraro; Caterina Tiozzo; Frederic Sala; Orquidea Rogers; Stijn De Langhe; Paul J Kemp; Daniela Riccardi; John Torday; Saverio Bellusci; Wei Shi; Sharon R Lubkin; Edwin Jesudason
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 2.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 3.  Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia.

Authors:  Shawn K Ahlfeld; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-11-28

4.  A role for epidermal growth factor receptor in idiopathic pulmonary fibrosis onset.

Authors:  Marcella Martinelli; Angela Maria Grazia Pacilli; Stefano Rivetti; Mattia Lauriola; Luca Fasano; Paolo Carbonara; Gabriella Mattei; Ilaria Valentini; Luca Scapoli; Rossella Solmi
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

5.  Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease.

Authors:  Elizabeth L Kramer; William D Hardie; Elizabeth M Mushaben; Thomas H Acciani; Patricia A Pastura; Thomas R Korfhagen; Gurjit Khurana Hershey; Jeffrey A Whitsett; Timothy D Le Cras
Journal:  J Appl Physiol (1985)       Date:  2011-09-08

6.  Early growth response-1 suppresses epidermal growth factor receptor-mediated airway hyperresponsiveness and lung remodeling in mice.

Authors:  Elizabeth L Kramer; Elizabeth M Mushaben; Patricia A Pastura; Thomas H Acciani; Gail H Deutsch; Gurjit K Khurana Hershey; Thomas R Korfhagen; William D Hardie; Jeffrey A Whitsett; Timothy D Le Cras
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-02       Impact factor: 6.914

7.  Genomic profile of matrix and vasculature remodeling in TGF-alpha induced pulmonary fibrosis.

Authors:  William D Hardie; Thomas R Korfhagen; Maureen A Sartor; Adrienne Prestridge; Mario Medvedovic; Timothy D Le Cras; Machiko Ikegami; Scott C Wesselkamper; Cynthia Davidson; Maggie Dietsch; William Nichols; Jeffrey A Whitsett; George D Leikauf
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-11       Impact factor: 6.914

8.  Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis.

Authors:  Nili Jin; Sung-Nam Cho; M Gabriela Raso; Ignacio Wistuba; Yvonne Smith; Yanan Yang; Jonathan M Kurie; Rudolph Yen; Christopher M Evans; Thomas Ludwig; Jae-Wook Jeong; Francesco J DeMayo
Journal:  Development       Date:  2009-08-26       Impact factor: 6.868

9.  Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2.

Authors:  Charles E Norton; Brad R S Broughton; Nikki L Jernigan; Benjimen R Walker; Thomas C Resta
Journal:  Antioxid Redox Signal       Date:  2012-10-18       Impact factor: 8.401

10.  Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.

Authors:  Timothy D Le Cras; Thomas R Korfhagen; Cynthia Davidson; Stephanie Schmidt; Matthew Fenchel; Machiko Ikegami; Jeffrey A Whitsett; William D Hardie
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.